View Future GrowthHubei DinglongLtd 過去の業績過去 基準チェック /56Hubei DinglongLtdは、平均年間41.6%の収益成長を遂げていますが、 Chemicals業界の収益は、年間 減少しています。収益は、平均年間5.6% 11.8%収益成長率で 成長しています。 Hubei DinglongLtdの自己資本利益率は15%であり、純利益率は21.5%です。主要情報41.57%収益成長率41.65%EPS成長率Chemicals 業界の成長12.10%収益成長率11.81%株主資本利益率15.02%ネット・マージン21.53%前回の決算情報31 Mar 2026最近の業績更新お知らせ • Dec 31Hubei Dinglong CO.,Ltd. to Report Fiscal Year 2025 Results on Mar 27, 2026Hubei Dinglong CO.,Ltd. announced that they will report fiscal year 2025 results on Mar 27, 2026お知らせ • Sep 30Hubei Dinglong CO.,Ltd. to Report Q3, 2025 Results on Oct 28, 2025Hubei Dinglong CO.,Ltd. announced that they will report Q3, 2025 results on Oct 28, 2025お知らせ • Jul 02Hubei Dinglong CO.,Ltd. to Report First Half, 2025 Results on Aug 22, 2025Hubei Dinglong CO.,Ltd. announced that they will report first half, 2025 results on Aug 22, 2025お知らせ • Mar 31Hubei Dinglong CO.,Ltd. to Report Q1, 2025 Results on Apr 29, 2025Hubei Dinglong CO.,Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025お知らせ • Dec 31Hubei Dinglong CO.,Ltd. to Report Fiscal Year 2024 Results on Apr 29, 2025Hubei Dinglong CO.,Ltd. announced that they will report fiscal year 2024 results on Apr 29, 2025Reported Earnings • Oct 25Third quarter 2024 earnings released: EPS: CN¥0.17 (vs CN¥0.093 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.17 (up from CN¥0.093 in 3Q 2023). Revenue: CN¥906.9m (up 27% from 3Q 2023). Net income: CN¥158.5m (up 97% from 3Q 2023). Profit margin: 18% (up from 11% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.すべての更新を表示Recent updatesBoard Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 3 highly experienced directors. Independent Director Xinping Xia was the last director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Mar 31+ 1 more updateHubei Dinglong CO.,Ltd., Annual General Meeting, Apr 24, 2026Hubei Dinglong CO.,Ltd., Annual General Meeting, Apr 24, 2026, at 14:30 China Standard Time. Location: 6F, Executive Building 1, No. 1, Dongjinghe Road, Wuhan Economic and Technological Development Zone, Hubei Chinaお知らせ • Dec 31Hubei Dinglong CO.,Ltd. to Report Fiscal Year 2025 Results on Mar 27, 2026Hubei Dinglong CO.,Ltd. announced that they will report fiscal year 2025 results on Mar 27, 2026お知らせ • Sep 30Hubei Dinglong CO.,Ltd. to Report Q3, 2025 Results on Oct 28, 2025Hubei Dinglong CO.,Ltd. announced that they will report Q3, 2025 results on Oct 28, 2025お知らせ • Jul 02Hubei Dinglong CO.,Ltd. to Report First Half, 2025 Results on Aug 22, 2025Hubei Dinglong CO.,Ltd. announced that they will report first half, 2025 results on Aug 22, 2025お知らせ • Jun 13Hubei Dinglong CO.,Ltd. (SZSE:300054) agreed to acquire Hubei Dinghui Microelectronic Materials Co., Ltd. from CCB Trust Co., Ltd. for CNY 240 million.Hubei Dinglong CO.,Ltd. (SZSE:300054) agreed to acquire Hubei Dinghui Microelectronic Materials Co., Ltd. from CCB Trust Co., Ltd. for CNY 240 million on June 10, 2025. A cash consideration of CNY 240 million will be paid by Hubei Dinglong CO.,Ltd. As part of consideration, CNY 240 million is paid towards common equity of Hubei Dinghui Microelectronic Materials Co., Ltd. Upon completion, Hubei Dinglong CO.,Ltd. will own 99.35% stake in Hubei Dinghui Microelectronic Materials Co., Ltd. For the period ending December 31, 2024, Hubei Dinghui Microelectronic Materials Co., Ltd. reported total revenue of CNY 717.23 million. As of December 31, 2024, Hubei Dinghui Microelectronic Materials Co., Ltd. reported total assets of CNY 1.35 billion and total common equity of CNY 963.08 million. The transaction has been approved by the board of Hubei Dinglong CO.,Ltd.お知らせ • May 22Hubei Dinglong Co.,Ltd. Approves Cash Dividend for the Year 2024Hubei Dinglong CO.,Ltd. held its Annual General Meeting of 2024 on 20 May 2025, during which the following proposal(s) was/were approved: 2024 profit distribution plan of Cash dividend/10 shares (tax included): CNY 1.00000000.お知らせ • Apr 29Hubei Dinglong CO.,Ltd., Annual General Meeting, May 20, 2025Hubei Dinglong CO.,Ltd., Annual General Meeting, May 20, 2025, at 15:00 China Standard Time.お知らせ • Mar 31Hubei Dinglong CO.,Ltd. to Report Q1, 2025 Results on Apr 29, 2025Hubei Dinglong CO.,Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025お知らせ • Dec 31Hubei Dinglong CO.,Ltd. to Report Fiscal Year 2024 Results on Apr 29, 2025Hubei Dinglong CO.,Ltd. announced that they will report fiscal year 2024 results on Apr 29, 2025Buy Or Sell Opportunity • Nov 08Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 42% to CN¥29.00. The fair value is estimated to be CN¥24.03, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 9.2% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 40% in 2 years. Earnings are forecast to grow by 100% in the next 2 years.Reported Earnings • Oct 25Third quarter 2024 earnings released: EPS: CN¥0.17 (vs CN¥0.093 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.17 (up from CN¥0.093 in 3Q 2023). Revenue: CN¥906.9m (up 27% from 3Q 2023). Net income: CN¥158.5m (up 97% from 3Q 2023). Profit margin: 18% (up from 11% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 30%After last week's 30% share price gain to CN¥23.85, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 16x in the Chemicals industry in China. Total returns to shareholders of 26% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥13.39 per share.お知らせ • Sep 30Hubei Dinglong CO.,Ltd. to Report Q3, 2024 Results on Oct 25, 2024Hubei Dinglong CO.,Ltd. announced that they will report Q3, 2024 results on Oct 25, 2024Reported Earnings • Aug 20Second quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.063 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.14 (up from CN¥0.063 in 2Q 2023). Revenue: CN¥810.8m (up 32% from 2Q 2023). Net income: CN¥136.3m (up 123% from 2Q 2023). Profit margin: 17% (up from 10.0% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.お知らせ • Jun 29Hubei Dinglong CO.,Ltd. to Report First Half, 2024 Results on Aug 20, 2024Hubei Dinglong CO.,Ltd. announced that they will report first half, 2024 results on Aug 20, 2024Reported Earnings • Apr 26First quarter 2024 earnings released: EPS: CN¥0.086 (vs CN¥0.037 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.086 (up from CN¥0.037 in 1Q 2023). Revenue: CN¥708.0m (up 30% from 1Q 2023). Net income: CN¥81.6m (up 135% from 1Q 2023). Profit margin: 12% (up from 6.4% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.お知らせ • Apr 10Hubei Dinglong CO.,Ltd., Annual General Meeting, May 14, 2024Hubei Dinglong CO.,Ltd., Annual General Meeting, May 14, 2024, at 15:00 China Standard Time. Location: The Company's Meeting Room, Wuhan, Hubei ChinaReported Earnings • Apr 10Full year 2023 earnings released: EPS: CN¥0.24 (vs CN¥0.42 in FY 2022)Full year 2023 results: EPS: CN¥0.24 (down from CN¥0.42 in FY 2022). Revenue: CN¥2.67b (down 2.0% from FY 2022). Net income: CN¥222.0m (down 43% from FY 2022). Profit margin: 8.3% (down from 14% in FY 2022). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.お知らせ • Mar 30Hubei Dinglong CO.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024Hubei Dinglong CO.,Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024Buy Or Sell Opportunity • Mar 26Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 10% to CN¥21.51. The fair value is estimated to be CN¥27.37, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 73%. Revenue is forecast to grow by 40% in 2 years. Earnings are forecast to grow by 116% in the next 2 years.お知らせ • Mar 16Hubei Dinglong CO.,Ltd. (SZSE:300054) agreed to acquire 6.83% stake in Wuhan Rouxian Technology Co., Ltd. from Qushui Dinglong Taihao Enterprise Management Co., Ltd. managed by Wuhan Paradise Silicon Valley Technology Innovation Asset Management Co., Ltd. for CNY 31.9 million.Hubei Dinglong CO.,Ltd. (SZSE:300054) agreed to acquire 6.83% stake in Wuhan Rouxian Technology Co., Ltd. from Qushui Dinglong Taihao Enterprise Management Co., Ltd. managed by Wuhan Paradise Silicon Valley Technology Innovation Asset Management Co., Ltd. for CNY 31.9 million on March 13, 2024. Transaction was financed by Hubei Dinglong's own funds. Transaction has already been approved by Wuhan Rouxian Technology Co., Ltd's board of director's.Valuation Update With 7 Day Price Move • Feb 08Investor sentiment improves as stock rises 17%After last week's 17% share price gain to CN¥20.42, the stock trades at a forward P/E ratio of 45x. Average forward P/E is 13x in the Chemicals industry in China. Negligible returns to shareholders over past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥27.66 per share.お知らせ • Feb 07Hubei Dinglong CO.,Ltd. (SZSE:300054) announces an Equity Buyback for CNY 200 million worth of its shares.Hubei Dinglong CO.,Ltd. (SZSE:300054) announces a share repurchase program. Under the program, the company will repurchase up to CNY 200 million worth of its shares. The shares will be repurchased at a price not more than CNY 30 per share. The purpose of the program is to use the repurchased shares for ESOP or equity incentives. The program is valid for a period of 3 months.お知らせ • Dec 30Hubei Dinglong CO.,Ltd. to Report Fiscal Year 2023 Results on Apr 10, 2024Hubei Dinglong CO.,Ltd. announced that they will report fiscal year 2023 results on Apr 10, 2024Reported Earnings • Oct 26Third quarter 2023 earnings released: EPS: CN¥0.093 (vs CN¥0.10 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.093 (down from CN¥0.10 in 3Q 2022). Revenue: CN¥713.2m (up 11% from 3Q 2022). Net income: CN¥80.4m (down 20% from 3Q 2022). Profit margin: 11% (down from 16% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.お知らせ • Sep 30Hubei Dinglong CO.,Ltd. to Report Q3, 2023 Results on Oct 26, 2023Hubei Dinglong CO.,Ltd. announced that they will report Q3, 2023 results on Oct 26, 2023Reported Earnings • Aug 19Second quarter 2023 earnings released: EPS: CN¥0.063 (vs CN¥0.13 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.063 (down from CN¥0.13 in 2Q 2022). Revenue: CN¥612.7m (down 18% from 2Q 2022). Net income: CN¥61.1m (down 50% from 2Q 2022). Profit margin: 10.0% (down from 17% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.お知らせ • Jul 01Hubei Dinglong CO.,Ltd. to Report First Half, 2023 Results on Aug 19, 2023Hubei Dinglong CO.,Ltd. announced that they will report first half, 2023 results on Aug 19, 2023お知らせ • Jun 09Hubei Dinglong Co.,Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on June 16, 2023Hubei Dinglong CO.,Ltd. announced final cash dividend/10 shares (tax included) of CNY 0.50000000 on A shares for the year 2022. Record date is June 15, 2023. Ex-date is May June 16, 2023. Payment date is June 16, 2023.Valuation Update With 7 Day Price Move • Apr 20Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥29.90, the stock trades at a forward P/E ratio of 51x. Average forward P/E is 16x in the Chemicals industry in China. Total returns to shareholders of 162% over the past three years.Reported Earnings • Apr 12Full year 2022 earnings released: EPS: CN¥0.42 (vs CN¥0.23 in FY 2021)Full year 2022 results: EPS: CN¥0.42 (up from CN¥0.23 in FY 2021). Revenue: CN¥2.72b (up 16% from FY 2021). Net income: CN¥390.0m (up 83% from FY 2021). Profit margin: 14% (up from 9.1% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has only increased by 31% per year, which means it is significantly lagging earnings growth.Board Change • Nov 16High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-Independent Director Minguang Su was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 28Third quarter 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.062 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.10 (up from CN¥0.062 in 3Q 2021). Revenue: CN¥642.9m (up 16% from 3Q 2021). Net income: CN¥100.3m (up 70% from 3Q 2021). Profit margin: 16% (up from 11% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 31% per year whereas the company’s share price has increased by 33% per year.Valuation Update With 7 Day Price Move • Oct 12Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to CN¥19.19, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 14x in the Chemicals industry in China. Total returns to shareholders of 105% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥17.39 per share.Valuation Update With 7 Day Price Move • Sep 08Investor sentiment improved over the past weekAfter last week's 17% share price gain to CN¥26.51, the stock trades at a forward P/E ratio of 52x. Average forward P/E is 17x in the Chemicals industry in China. Total returns to shareholders of 154% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥19.08 per share.Reported Earnings • Aug 20Second quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.058 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.14 (up from CN¥0.058 in 2Q 2021). Revenue: CN¥742.8m (up 29% from 2Q 2021). Net income: CN¥123.1m (up 129% from 2Q 2021). Profit margin: 17% (up from 9.3% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 29%, compared to a 41% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 38% per year, which means it is well ahead of earnings.Board Change • Jun 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-Independent Director Minguang Su was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 27First quarter 2022 earnings released: EPS: CN¥0.076 (vs CN¥0.04 in 1Q 2021)First quarter 2022 results: EPS: CN¥0.076 (up from CN¥0.04 in 1Q 2021). Revenue: CN¥569.7m (up 9.6% from 1Q 2021). Net income: CN¥71.4m (up 90% from 1Q 2021). Profit margin: 13% (up from 7.2% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 29%, compared to a 43% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has increased by 19% per year, which means it is well ahead of earnings.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. 3 independent directors (8 non-independent directors). Independent Director Xiao Ji was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Apr 16Full year 2021 earnings released: EPS: CN¥0.23 (vs CN¥0.17 loss in FY 2020)Full year 2021 results: EPS: CN¥0.23 (up from CN¥0.17 loss in FY 2020). Revenue: CN¥2.36b (up 30% from FY 2020). Net income: CN¥213.5m (up CN¥373.3m from FY 2020). Profit margin: 9.1% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Over the next year, revenue is forecast to grow 15%, compared to a 51% growth forecast for the industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 105 percentage points per year, which is a significant difference in performance.Reported Earnings • Oct 28Third quarter 2021 earnings released: EPS CN¥0.062 (vs CN¥0.04 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥554.9m (up 25% from 3Q 2020). Net income: CN¥59.2m (up 45% from 3Q 2020). Profit margin: 11% (up from 9.2% in 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 159 percentage points per year, which is a significant difference in performance.Reported Earnings • Aug 19Second quarter 2021 earnings released: EPS CN¥0.06 (vs CN¥0.18 in 2Q 2020)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥576.4m (up 9.2% from 2Q 2020). Net income: CN¥53.9m (down 71% from 2Q 2020). Profit margin: 9.3% (down from 35% in 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 140 percentage points per year, which is a significant difference in performance.Reported Earnings • Apr 10Full year 2020 earnings released: CN¥0.17 loss per share (vs CN¥0.036 profit in FY 2019)The company reported a mediocre full year result with weaker earnings and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: CN¥1.82b (up 58% from FY 2019). Net loss: CN¥159.8m (down CN¥193.9m from profit in FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 82 percentage points per year, which is a significant difference in performance.Is New 90 Day High Low • Jan 21New 90-day high: CN¥23.44The company is up 52% from its price of CN¥15.38 on 23 October 2020. The Chinese market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 19% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥12.87 per share.Is New 90 Day High Low • Jan 05New 90-day high: CN¥19.30The company is up 23% from its price of CN¥15.70 on 30 September 2020. The Chinese market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 16% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥12.94 per share.Is New 90 Day High Low • Dec 17New 90-day high: CN¥17.45The company is up 5.0% from its price of CN¥16.61 on 18 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company outperformed over that time. However, its price trend is similar to the Chemicals industry, which is also up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥12.97 per share.Reported Earnings • Oct 29Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥97.7m, down 59% from the prior year. Total revenue was CN¥1.61b over the last 12 months, up 40% from the prior year.Is New 90 Day High Low • Oct 23New 90-day low: CN¥15.38The company is down 15% from its price of CN¥18.06 on 24 July 2020. The Chinese market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥2.06 per share.Is New 90 Day High Low • Sep 28New 90-day low: CN¥15.59The company is down 6.0% from its price of CN¥16.60 on 30 June 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥2.03 per share.収支内訳Hubei DinglongLtd の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史XSEC:300054 収益、費用、利益 ( )CNY Millions日付収益収益G+A経費研究開発費31 Mar 263,85683042654031 Dec 253,66072042451530 Sep 253,61066444851230 Jun 253,55061444949031 Mar 253,45458044147531 Dec 243,33852142545930 Sep 243,22042239443530 Jun 243,02734436542331 Mar 242,82826935639431 Dec 232,66722233837730 Sep 232,63927232137230 Jun 232,56829131434631 Mar 232,69835331033631 Dec 222,72139031831330 Sep 222,66035831029930 Jun 222,57231731927631 Mar 222,40624731026531 Dec 212,35621429625230 Sep 212,214-24936123830 Jun 212,102-26834621531 Mar 212,054-13734318631 Dec 201,817-16033016230 Sep 201,6069829413030 Jun 201,4019326712131 Mar 201,161-523611531 Dec 191,1493422011430 Sep 191,14624017811130 Jun 191,22430217211031 Mar 191,29229817211231 Dec 181,33829317810330 Sep 181,4433391639730 Jun 181,52831213213131 Mar 181,62631115310431 Dec 171,7003361678430 Sep 171,6322941935830 Jun 171,624296250031 Mar 171,457272226031 Dec 161,306240207030 Sep 161,215218174030 Jun 161,083186152031 Mar 161,051163143031 Dec 151,050159143030 Sep 151,007155143030 Jun 159801451370質の高い収益: 300054は 高品質の収益 を持っています。利益率の向上: 300054の現在の純利益率 (21.5%)は、昨年(16.8%)よりも高くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: 300054過去 5 年間で収益を上げており、収益は年間41.6%増加しています。成長の加速: 300054の過去 1 年間の収益成長率 ( 43.1% ) は、5 年間の平均 ( 年間41.6%を上回っています。収益対業界: 300054の過去 1 年間の収益成長率 ( 43.1% ) はChemicals業界3.7%を上回りました。株主資本利益率高いROE: 300054の 自己資本利益率 ( 15% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YMaterials 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 04:19終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Hubei Dinglong CO.,Ltd. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9 アナリスト機関null nullChina International Capital Corporation LimitedYilin HouChina International Capital Corporation LimitedAda WangChina Stock Investment Research Co. Ltd. (GZ500..com)6 その他のアナリストを表示
お知らせ • Dec 31Hubei Dinglong CO.,Ltd. to Report Fiscal Year 2025 Results on Mar 27, 2026Hubei Dinglong CO.,Ltd. announced that they will report fiscal year 2025 results on Mar 27, 2026
お知らせ • Sep 30Hubei Dinglong CO.,Ltd. to Report Q3, 2025 Results on Oct 28, 2025Hubei Dinglong CO.,Ltd. announced that they will report Q3, 2025 results on Oct 28, 2025
お知らせ • Jul 02Hubei Dinglong CO.,Ltd. to Report First Half, 2025 Results on Aug 22, 2025Hubei Dinglong CO.,Ltd. announced that they will report first half, 2025 results on Aug 22, 2025
お知らせ • Mar 31Hubei Dinglong CO.,Ltd. to Report Q1, 2025 Results on Apr 29, 2025Hubei Dinglong CO.,Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025
お知らせ • Dec 31Hubei Dinglong CO.,Ltd. to Report Fiscal Year 2024 Results on Apr 29, 2025Hubei Dinglong CO.,Ltd. announced that they will report fiscal year 2024 results on Apr 29, 2025
Reported Earnings • Oct 25Third quarter 2024 earnings released: EPS: CN¥0.17 (vs CN¥0.093 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.17 (up from CN¥0.093 in 3Q 2023). Revenue: CN¥906.9m (up 27% from 3Q 2023). Net income: CN¥158.5m (up 97% from 3Q 2023). Profit margin: 18% (up from 11% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 3 highly experienced directors. Independent Director Xinping Xia was the last director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Mar 31+ 1 more updateHubei Dinglong CO.,Ltd., Annual General Meeting, Apr 24, 2026Hubei Dinglong CO.,Ltd., Annual General Meeting, Apr 24, 2026, at 14:30 China Standard Time. Location: 6F, Executive Building 1, No. 1, Dongjinghe Road, Wuhan Economic and Technological Development Zone, Hubei China
お知らせ • Dec 31Hubei Dinglong CO.,Ltd. to Report Fiscal Year 2025 Results on Mar 27, 2026Hubei Dinglong CO.,Ltd. announced that they will report fiscal year 2025 results on Mar 27, 2026
お知らせ • Sep 30Hubei Dinglong CO.,Ltd. to Report Q3, 2025 Results on Oct 28, 2025Hubei Dinglong CO.,Ltd. announced that they will report Q3, 2025 results on Oct 28, 2025
お知らせ • Jul 02Hubei Dinglong CO.,Ltd. to Report First Half, 2025 Results on Aug 22, 2025Hubei Dinglong CO.,Ltd. announced that they will report first half, 2025 results on Aug 22, 2025
お知らせ • Jun 13Hubei Dinglong CO.,Ltd. (SZSE:300054) agreed to acquire Hubei Dinghui Microelectronic Materials Co., Ltd. from CCB Trust Co., Ltd. for CNY 240 million.Hubei Dinglong CO.,Ltd. (SZSE:300054) agreed to acquire Hubei Dinghui Microelectronic Materials Co., Ltd. from CCB Trust Co., Ltd. for CNY 240 million on June 10, 2025. A cash consideration of CNY 240 million will be paid by Hubei Dinglong CO.,Ltd. As part of consideration, CNY 240 million is paid towards common equity of Hubei Dinghui Microelectronic Materials Co., Ltd. Upon completion, Hubei Dinglong CO.,Ltd. will own 99.35% stake in Hubei Dinghui Microelectronic Materials Co., Ltd. For the period ending December 31, 2024, Hubei Dinghui Microelectronic Materials Co., Ltd. reported total revenue of CNY 717.23 million. As of December 31, 2024, Hubei Dinghui Microelectronic Materials Co., Ltd. reported total assets of CNY 1.35 billion and total common equity of CNY 963.08 million. The transaction has been approved by the board of Hubei Dinglong CO.,Ltd.
お知らせ • May 22Hubei Dinglong Co.,Ltd. Approves Cash Dividend for the Year 2024Hubei Dinglong CO.,Ltd. held its Annual General Meeting of 2024 on 20 May 2025, during which the following proposal(s) was/were approved: 2024 profit distribution plan of Cash dividend/10 shares (tax included): CNY 1.00000000.
お知らせ • Apr 29Hubei Dinglong CO.,Ltd., Annual General Meeting, May 20, 2025Hubei Dinglong CO.,Ltd., Annual General Meeting, May 20, 2025, at 15:00 China Standard Time.
お知らせ • Mar 31Hubei Dinglong CO.,Ltd. to Report Q1, 2025 Results on Apr 29, 2025Hubei Dinglong CO.,Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025
お知らせ • Dec 31Hubei Dinglong CO.,Ltd. to Report Fiscal Year 2024 Results on Apr 29, 2025Hubei Dinglong CO.,Ltd. announced that they will report fiscal year 2024 results on Apr 29, 2025
Buy Or Sell Opportunity • Nov 08Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 42% to CN¥29.00. The fair value is estimated to be CN¥24.03, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 9.2% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 40% in 2 years. Earnings are forecast to grow by 100% in the next 2 years.
Reported Earnings • Oct 25Third quarter 2024 earnings released: EPS: CN¥0.17 (vs CN¥0.093 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.17 (up from CN¥0.093 in 3Q 2023). Revenue: CN¥906.9m (up 27% from 3Q 2023). Net income: CN¥158.5m (up 97% from 3Q 2023). Profit margin: 18% (up from 11% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 30%After last week's 30% share price gain to CN¥23.85, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 16x in the Chemicals industry in China. Total returns to shareholders of 26% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥13.39 per share.
お知らせ • Sep 30Hubei Dinglong CO.,Ltd. to Report Q3, 2024 Results on Oct 25, 2024Hubei Dinglong CO.,Ltd. announced that they will report Q3, 2024 results on Oct 25, 2024
Reported Earnings • Aug 20Second quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.063 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.14 (up from CN¥0.063 in 2Q 2023). Revenue: CN¥810.8m (up 32% from 2Q 2023). Net income: CN¥136.3m (up 123% from 2Q 2023). Profit margin: 17% (up from 10.0% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
お知らせ • Jun 29Hubei Dinglong CO.,Ltd. to Report First Half, 2024 Results on Aug 20, 2024Hubei Dinglong CO.,Ltd. announced that they will report first half, 2024 results on Aug 20, 2024
Reported Earnings • Apr 26First quarter 2024 earnings released: EPS: CN¥0.086 (vs CN¥0.037 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.086 (up from CN¥0.037 in 1Q 2023). Revenue: CN¥708.0m (up 30% from 1Q 2023). Net income: CN¥81.6m (up 135% from 1Q 2023). Profit margin: 12% (up from 6.4% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.
お知らせ • Apr 10Hubei Dinglong CO.,Ltd., Annual General Meeting, May 14, 2024Hubei Dinglong CO.,Ltd., Annual General Meeting, May 14, 2024, at 15:00 China Standard Time. Location: The Company's Meeting Room, Wuhan, Hubei China
Reported Earnings • Apr 10Full year 2023 earnings released: EPS: CN¥0.24 (vs CN¥0.42 in FY 2022)Full year 2023 results: EPS: CN¥0.24 (down from CN¥0.42 in FY 2022). Revenue: CN¥2.67b (down 2.0% from FY 2022). Net income: CN¥222.0m (down 43% from FY 2022). Profit margin: 8.3% (down from 14% in FY 2022). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.
お知らせ • Mar 30Hubei Dinglong CO.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024Hubei Dinglong CO.,Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024
Buy Or Sell Opportunity • Mar 26Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 10% to CN¥21.51. The fair value is estimated to be CN¥27.37, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 73%. Revenue is forecast to grow by 40% in 2 years. Earnings are forecast to grow by 116% in the next 2 years.
お知らせ • Mar 16Hubei Dinglong CO.,Ltd. (SZSE:300054) agreed to acquire 6.83% stake in Wuhan Rouxian Technology Co., Ltd. from Qushui Dinglong Taihao Enterprise Management Co., Ltd. managed by Wuhan Paradise Silicon Valley Technology Innovation Asset Management Co., Ltd. for CNY 31.9 million.Hubei Dinglong CO.,Ltd. (SZSE:300054) agreed to acquire 6.83% stake in Wuhan Rouxian Technology Co., Ltd. from Qushui Dinglong Taihao Enterprise Management Co., Ltd. managed by Wuhan Paradise Silicon Valley Technology Innovation Asset Management Co., Ltd. for CNY 31.9 million on March 13, 2024. Transaction was financed by Hubei Dinglong's own funds. Transaction has already been approved by Wuhan Rouxian Technology Co., Ltd's board of director's.
Valuation Update With 7 Day Price Move • Feb 08Investor sentiment improves as stock rises 17%After last week's 17% share price gain to CN¥20.42, the stock trades at a forward P/E ratio of 45x. Average forward P/E is 13x in the Chemicals industry in China. Negligible returns to shareholders over past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥27.66 per share.
お知らせ • Feb 07Hubei Dinglong CO.,Ltd. (SZSE:300054) announces an Equity Buyback for CNY 200 million worth of its shares.Hubei Dinglong CO.,Ltd. (SZSE:300054) announces a share repurchase program. Under the program, the company will repurchase up to CNY 200 million worth of its shares. The shares will be repurchased at a price not more than CNY 30 per share. The purpose of the program is to use the repurchased shares for ESOP or equity incentives. The program is valid for a period of 3 months.
お知らせ • Dec 30Hubei Dinglong CO.,Ltd. to Report Fiscal Year 2023 Results on Apr 10, 2024Hubei Dinglong CO.,Ltd. announced that they will report fiscal year 2023 results on Apr 10, 2024
Reported Earnings • Oct 26Third quarter 2023 earnings released: EPS: CN¥0.093 (vs CN¥0.10 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.093 (down from CN¥0.10 in 3Q 2022). Revenue: CN¥713.2m (up 11% from 3Q 2022). Net income: CN¥80.4m (down 20% from 3Q 2022). Profit margin: 11% (down from 16% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.
お知らせ • Sep 30Hubei Dinglong CO.,Ltd. to Report Q3, 2023 Results on Oct 26, 2023Hubei Dinglong CO.,Ltd. announced that they will report Q3, 2023 results on Oct 26, 2023
Reported Earnings • Aug 19Second quarter 2023 earnings released: EPS: CN¥0.063 (vs CN¥0.13 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.063 (down from CN¥0.13 in 2Q 2022). Revenue: CN¥612.7m (down 18% from 2Q 2022). Net income: CN¥61.1m (down 50% from 2Q 2022). Profit margin: 10.0% (down from 17% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
お知らせ • Jul 01Hubei Dinglong CO.,Ltd. to Report First Half, 2023 Results on Aug 19, 2023Hubei Dinglong CO.,Ltd. announced that they will report first half, 2023 results on Aug 19, 2023
お知らせ • Jun 09Hubei Dinglong Co.,Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on June 16, 2023Hubei Dinglong CO.,Ltd. announced final cash dividend/10 shares (tax included) of CNY 0.50000000 on A shares for the year 2022. Record date is June 15, 2023. Ex-date is May June 16, 2023. Payment date is June 16, 2023.
Valuation Update With 7 Day Price Move • Apr 20Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥29.90, the stock trades at a forward P/E ratio of 51x. Average forward P/E is 16x in the Chemicals industry in China. Total returns to shareholders of 162% over the past three years.
Reported Earnings • Apr 12Full year 2022 earnings released: EPS: CN¥0.42 (vs CN¥0.23 in FY 2021)Full year 2022 results: EPS: CN¥0.42 (up from CN¥0.23 in FY 2021). Revenue: CN¥2.72b (up 16% from FY 2021). Net income: CN¥390.0m (up 83% from FY 2021). Profit margin: 14% (up from 9.1% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has only increased by 31% per year, which means it is significantly lagging earnings growth.
Board Change • Nov 16High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-Independent Director Minguang Su was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 28Third quarter 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.062 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.10 (up from CN¥0.062 in 3Q 2021). Revenue: CN¥642.9m (up 16% from 3Q 2021). Net income: CN¥100.3m (up 70% from 3Q 2021). Profit margin: 16% (up from 11% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 31% per year whereas the company’s share price has increased by 33% per year.
Valuation Update With 7 Day Price Move • Oct 12Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to CN¥19.19, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 14x in the Chemicals industry in China. Total returns to shareholders of 105% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥17.39 per share.
Valuation Update With 7 Day Price Move • Sep 08Investor sentiment improved over the past weekAfter last week's 17% share price gain to CN¥26.51, the stock trades at a forward P/E ratio of 52x. Average forward P/E is 17x in the Chemicals industry in China. Total returns to shareholders of 154% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥19.08 per share.
Reported Earnings • Aug 20Second quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.058 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.14 (up from CN¥0.058 in 2Q 2021). Revenue: CN¥742.8m (up 29% from 2Q 2021). Net income: CN¥123.1m (up 129% from 2Q 2021). Profit margin: 17% (up from 9.3% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 29%, compared to a 41% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 38% per year, which means it is well ahead of earnings.
Board Change • Jun 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-Independent Director Minguang Su was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 27First quarter 2022 earnings released: EPS: CN¥0.076 (vs CN¥0.04 in 1Q 2021)First quarter 2022 results: EPS: CN¥0.076 (up from CN¥0.04 in 1Q 2021). Revenue: CN¥569.7m (up 9.6% from 1Q 2021). Net income: CN¥71.4m (up 90% from 1Q 2021). Profit margin: 13% (up from 7.2% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 29%, compared to a 43% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has increased by 19% per year, which means it is well ahead of earnings.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. 3 independent directors (8 non-independent directors). Independent Director Xiao Ji was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Apr 16Full year 2021 earnings released: EPS: CN¥0.23 (vs CN¥0.17 loss in FY 2020)Full year 2021 results: EPS: CN¥0.23 (up from CN¥0.17 loss in FY 2020). Revenue: CN¥2.36b (up 30% from FY 2020). Net income: CN¥213.5m (up CN¥373.3m from FY 2020). Profit margin: 9.1% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Over the next year, revenue is forecast to grow 15%, compared to a 51% growth forecast for the industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 105 percentage points per year, which is a significant difference in performance.
Reported Earnings • Oct 28Third quarter 2021 earnings released: EPS CN¥0.062 (vs CN¥0.04 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥554.9m (up 25% from 3Q 2020). Net income: CN¥59.2m (up 45% from 3Q 2020). Profit margin: 11% (up from 9.2% in 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 159 percentage points per year, which is a significant difference in performance.
Reported Earnings • Aug 19Second quarter 2021 earnings released: EPS CN¥0.06 (vs CN¥0.18 in 2Q 2020)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥576.4m (up 9.2% from 2Q 2020). Net income: CN¥53.9m (down 71% from 2Q 2020). Profit margin: 9.3% (down from 35% in 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 140 percentage points per year, which is a significant difference in performance.
Reported Earnings • Apr 10Full year 2020 earnings released: CN¥0.17 loss per share (vs CN¥0.036 profit in FY 2019)The company reported a mediocre full year result with weaker earnings and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: CN¥1.82b (up 58% from FY 2019). Net loss: CN¥159.8m (down CN¥193.9m from profit in FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 82 percentage points per year, which is a significant difference in performance.
Is New 90 Day High Low • Jan 21New 90-day high: CN¥23.44The company is up 52% from its price of CN¥15.38 on 23 October 2020. The Chinese market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 19% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥12.87 per share.
Is New 90 Day High Low • Jan 05New 90-day high: CN¥19.30The company is up 23% from its price of CN¥15.70 on 30 September 2020. The Chinese market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 16% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥12.94 per share.
Is New 90 Day High Low • Dec 17New 90-day high: CN¥17.45The company is up 5.0% from its price of CN¥16.61 on 18 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company outperformed over that time. However, its price trend is similar to the Chemicals industry, which is also up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥12.97 per share.
Reported Earnings • Oct 29Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥97.7m, down 59% from the prior year. Total revenue was CN¥1.61b over the last 12 months, up 40% from the prior year.
Is New 90 Day High Low • Oct 23New 90-day low: CN¥15.38The company is down 15% from its price of CN¥18.06 on 24 July 2020. The Chinese market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥2.06 per share.
Is New 90 Day High Low • Sep 28New 90-day low: CN¥15.59The company is down 6.0% from its price of CN¥16.60 on 30 June 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥2.03 per share.